Cognition Therapeutics, Inc. (CGTX)
0.9796
-0.01
(-1.05%)
USD |
NASDAQ |
Sep 10, 16:00
0.95
-0.03
(-3.02%)
After-Hours: 20:00
Cognition Therapeutics Enterprise Value : 59.93M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 59.93M |
| September 08, 2026 | 61.83M |
| September 04, 2026 | 63.73M |
| September 03, 2026 | 65.64M |
| September 02, 2026 | 65.64M |
| September 01, 2026 | 61.83M |
| August 31, 2026 | 63.73M |
| August 28, 2026 | 62.78M |
| August 27, 2026 | 66.59M |
| August 26, 2026 | 65.64M |
| August 25, 2026 | 63.73M |
| August 24, 2026 | 59.41M |
| August 21, 2026 | 60.49M |
| August 20, 2026 | 56.77M |
| August 19, 2026 | 58.87M |
| August 18, 2026 | 59.16M |
| August 17, 2026 | 62.78M |
| August 14, 2026 | 61.83M |
| August 13, 2026 | 64.68M |
| August 12, 2026 | 64.68M |
| August 11, 2026 | 62.78M |
| August 10, 2026 | 65.64M |
| August 07, 2026 | 68.49M |
| August 06, 2026 | 73.24M |
| August 05, 2026 | 66.59M |
| Date | Value |
|---|---|
| August 04, 2026 | 59.56M |
| August 03, 2026 | 50.57M |
| July 31, 2026 | 50.39M |
| July 30, 2026 | 52.90M |
| July 29, 2026 | 51.48M |
| July 28, 2026 | 53.61M |
| July 27, 2026 | 56.07M |
| July 24, 2026 | 53.23M |
| July 23, 2026 | 57.10M |
| July 22, 2026 | 57.28M |
| July 21, 2026 | 60.88M |
| July 20, 2026 | 56.00M |
| July 17, 2026 | 57.16M |
| July 16, 2026 | 55.18M |
| July 15, 2026 | 56.04M |
| July 14, 2026 | 61.83M |
| July 13, 2026 | 62.78M |
| July 10, 2026 | 69.44M |
| July 09, 2026 | 69.44M |
| July 08, 2026 | 67.54M |
| July 07, 2026 | 68.49M |
| July 06, 2026 | 67.54M |
| July 02, 2026 | 77.04M |
| July 01, 2026 | 73.24M |
| June 30, 2026 | 75.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zevra Therapeutics, Inc. | 494.40M |
| Bristol Myers Squibb Co. | 165.58B |
| Structure Therapeutics, Inc. | 1.600B |
| ANI Pharmaceuticals, Inc. | 1.859B |
| Corcept Therapeutics, Inc. | 12.19B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.932M |
| Total Expenses (Quarterly) | 3.932M |
| EPS Diluted (Quarterly) | -0.0434 |
| Earnings Yield | -19.95% |
| Normalized Earnings Yield | -19.96 |